Refine your search
-
Authors
-
Item types
-
Topics
- *Alemtuzumab/tu [Therapeutic Use]
- *Antibodies, Monoclonal, Humanized/tu [Therapeutic Use]
- *Breast Neoplasms/dt [Drug Therapy]
- *Breast Neoplasms/ge [Genetics]
- *Multiple Sclerosis, Relapsing-Remitting/dt [Drug Therapy]
- *Receptor, erbB-2/ge [Genetics]
- Alemtuzumab/ae [Adverse Effects]
- Alemtuzumab/pk [Pharmacokinetics]
- Antibodies, Monoclonal, Humanized/ae [Adverse Effects]
- Antibodies, Monoclonal, Humanized/pd [Pharmacology]
- Antibodies, Monoclonal, Humanized/pk [Pharmacokinetics]
- CD52 Antigen/im [Immunology]
- Clinical Trials as Topic
- Clinical Trials, Phase I as Topic
- Clinical Trials, Phase II as Topic
- Clinical Trials, Phase III as Topic
- Drug Approval
- Drug Evaluation, Preclinical
- Humans
- Product Surveillance, Postmarketing
- Show more
- Show less
-
Collections
-
Languages